Moleculin Biotech (MBRX) Receivables - Other (2019 - 2025)
Moleculin Biotech (MBRX) has 7 years of Receivables - Other data on record, last reported at $2000.0 in Q3 2025.
- For Q3 2025, Receivables - Other changed N/A year-over-year to $2000.0; the TTM value through Sep 2025 reached $2000.0, changed N/A, while the annual FY2024 figure was $16000.0, 83.16% down from the prior year.
- Receivables - Other reached $2000.0 in Q3 2025 per MBRX's latest filing, up from $1000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $95000.0 in Q4 2023 and bottomed at $1000.0 in Q2 2025.
- Average Receivables - Other over 5 years is $15333.3, with a median of $5000.0 recorded in 2022.
- Peak YoY movement for Receivables - Other: plummeted 91.3% in 2022, then soared 4650.0% in 2023.
- A 5-year view of Receivables - Other shows it stood at $23000.0 in 2021, then tumbled by 91.3% to $2000.0 in 2022, then skyrocketed by 4650.0% to $95000.0 in 2023, then crashed by 83.16% to $16000.0 in 2024, then plummeted by 87.5% to $2000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $2000.0 in Q3 2025, $1000.0 in Q2 2025, and $2000.0 in Q1 2025.